Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.
You may also be interested in...
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.
Australian Teeth Whitener Marketer Frowns On Industry Self-Regulation Referencing US Laws
HiSmile appeals NAD recommendation following review on P&G challenge to discontinue ad claims on its website and in social media videos stating peroxide-containing whitening products are “painful” or cause pain, break down and impact gums and teeth, or “damage” gums.